DeCure for Esophageal atresia/tracheoesophageal fistula
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for esophageal atresia/tracheoesophageal fistula — screening already-approved drugs against its 20-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEsophageal atresia/tracheoesophageal fistula maps to a 20-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for esophageal atresia/tracheoesophageal fistula is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
adaptor related protein complex 1 subunit gamma 2 (AP1G2) — AP1G2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pdodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2YMT · 1.802 Å · ligand 1,3-PROPANDIOL (PDO). Experimental structure, not a prediction.
What the evidence adds up to
The Surgical Section of the American Academy of Pediatrics surveyed its members on outcomes for esophageal atresia and tracheoesophageal fistula over the five years ending January 1963. Data on 1,058 patients was received and processed by computer. The results were not easily summarised.
A 2016 review notes that esophageal atresia always requires surgical resection. Postoperative complications include recurrent tracheoesophageal fistula (rTEF). The review describes perioperative skills, latest advances, and optimal techniques for managing rTEF, and summarises the advantages, disadvantages, and indications of various endoscopic therapies. Future trends are predicted.
A 2025 case report describes an adult patient who developed a very-delayed-onset large tracheoesophageal fistula and near esophagocutaneous fistula after colonic interposition for esophageal atresia. The fistula was treated with serial multimodal endoscopic management using over-the-scope clips, argon plasma coagulation, and endoscopic suturing. No numbers of patients, response rates, or survival data are given.
What is still missing are prospective trials comparing endoscopic techniques, standardised outcome measures for recurrent fistula closure, and any data on long-term survival or quality of life after these interventions. Patient stratification by age, fistula size, and prior surgical history is not established.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PEDIATRICS · 1964 · 236 citations
ESOPHAGEAL ATRESIA AND TRACHEOESOPHAGEAL FISTULA
AbstractThe members of the Surgical Section of the American Academy of Pedatrics were surveyed regarding their results in treating patients with esophageal atresia and tracheoesophageal fistula for the five-year period ending January 1, 1963. Information on 1,058 patients was received. The data was processed with the aid of a computer and the results, not easily summarized, have been presented.
Treatment advances for recurrent tracheoesophageal fistula after esophageal atresia operations
AbstractEsophageal atresia, a common congenital malformations of digestive system, always requires surgical resection. However there are a variety of postoperative complications, including recurrent tracheoesophageal fistula (rTEF). This review has described the perioperative skills, latest advances and optimal techniques of managing rTEF. Also the advantages, disadvantages and indications of various endoscopic therapies for rTEF were summarized. Future trends are predicated.
Key words:
Esophageal atresia; Esophagotracheal fistula
ACG Case Reports Journal · 2025 · 0 citations · open access
Endoscopic Treatment of Very-Delayed-Onset Tracheoesophageal and Esophagocutaneous Fistulae after Colonic Interposition for Esophageal Atresia
AbstractTracheoesophageal fistula can develop after surgical repair of congenital esophageal atresia, but it usually occurs in pediatric populations. Here, we present an adult patient with an unusual very-delayed onset of a large tracheoesophageal fistula and near esophagocutaneous fistula treated with serial multimodal endoscopic management featuring over-the-scope clips, argon plasma coagulation, and endoscopic suturing.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
